PolyPid (PYPD) Other Non-Current Assets (2019 - 2026)
PolyPid (PYPD) posted Other Non-Current Assets of $369000.0 for Q1 2026, up 18.65% sequentially from $311000.0 in Q4 2025, and up 29.93% YoY from $284000.0 in Q1 2025.
PolyPid (PYPD) Other Non-Current Assets (2019 - 2026) Analysis & Trends
PolyPid has reported Other Non-Current Assets for 8 years, with the latest figure at $369000.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 29.93% year-over-year to $369000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $369000.0 (up 29.93% YoY) and the FY2025 annual result came in at $311000.0, up 12.27% from the prior year.
- Other Non-Current Assets grew to $369000.0 in Q1 2026 per PYPD's latest filing, from $311000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $4.0 million in Q4 2022 and troughed at $87000.0 in Q4 2023.
- A 5-year average of $522647.1 and a median of $284000.0 in 2025 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets slumped 97.85% in 2023, then jumped 218.39% in 2024.
- Over 5 years, Other Non-Current Assets stood at $4.0 million in 2022, then plunged by 97.85% to $87000.0 in 2023, then surged by 218.39% to $277000.0 in 2024, then gained by 12.27% to $311000.0 in 2025, then gained by 18.65% to $369000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $369000.0, $311000.0, and $304000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - | 327,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 327,000.00 |
| Mar 31, 2026 | 369,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Sep 30, 2025 | 304,000.00 |
| Jun 30, 2025 | 298,000.00 |
| Mar 31, 2025 | 284,000.00 |
| Dec 31, 2024 | 277,000.00 |
| Sep 30, 2024 | 269,000.00 |
| Jun 30, 2024 | 257,000.00 |
| Mar 31, 2024 | 218,000.00 |
| Dec 31, 2023 | 87,000.00 |
| Sep 30, 2023 | 101,000.00 |
| Jun 30, 2023 | 89,000.00 |
| Mar 31, 2023 | 107,000.00 |
| Dec 31, 2022 | 4.04 Mn |
| Sep 30, 2022 | 603,000.00 |
| Jun 30, 2022 | 618,000.00 |
| Mar 31, 2022 | 651,000.00 |
| Dec 31, 2021 | 22.38 Mn |
| Sep 30, 2021 | 2.43 Mn |